Bodil Willumsen

1 minute reading time

Bodil Willumsen, Ph.D., is an expert in gene therapy manufacturing and works as a CMC consultant in the field of cell and gene therapy. She has led the CMC team at LentiCure since October 2023.

  • CMC leader at LentiCure since October 2023 

  • Director of Supplier Relationship Teams, between 2016 and 2023, and Technical Project Leader, between 2012 and 2016, at Novartis. During this period, Bodil was responsible for the development, manufacturing and commercialization of the lentiviral vector for Kymriah; the first CAR-T cell therapy to reach the market. She worked with various cell and gene therapy products and was ultimately responsible for the suppliers of Luxturna, an AAV gene therapy for inherited retinal diseases. 

  • Associate director, between 2011 and 2012, and Project Manager, between 2008 and 2010, in CMC at Genmab. More information on LinkedIn.

Bodil has more than 25 years of experience in CMC and biopharmaceutical product development, from preclinical to commercial product. Her experience covers a wide range of biological platforms, from viral vectors, CAR-T and gene therapies to recombinant proteins and ADCs. Four of the products she worked on in the development phases are now commercial products. 

Bodil Willumsen